Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
BMRN
BMRN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest BMRN ETF News Today | Earnings, Events & Price Alerts
BMRN News
FDA Faces Criticism Amid Innovation Challenges
12h ago
CNBC
BioMarin's Drug Approved by FDA for PKU Treatment
1d ago
Benzinga
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients
4d ago
NASDAQ.COM
FDA Approves PALYNZIQ for Pediatric PKU Treatment in Adolescents
4d ago
PRnewswire
FDA Approves PALYNZIQ for Adolescent PKU Treatment
4d ago
Newsfilter
FDA Grants Approval for Biomarin's Palynziq® (Pegvaliase-PQPZ) for Adolescents Aged 12 and Up with Phenylketonuria (PKU)
4d ago
moomoo
BioMarin Reports Mixed Q4 Results with Earnings Miss
6d ago
Benzinga
BioMarin Reports Strong 2025 Earnings Growth
Feb 24 2026
seekingalpha
BioMarin Pharmaceutical Q4 Earnings Beat Expectations Despite EPS Miss
Feb 23 2026
seekingalpha
BioMarin to Host Q4 2025 Earnings Call on February 23, 2026
Feb 23 2026
NASDAQ.COM
BioMarin Pharmaceutical Set to Release Q4 Earnings on February 23
Feb 20 2026
seekingalpha
Phenylketonuria Treatment Market Outlook Analysis
Feb 18 2026
Newsfilter
BioMarin to Host Q4 2025 Earnings Call on February 23, 2026
Feb 17 2026
PRnewswire
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
Feb 12 2026
Benzinga
BioMarin Pharmaceutical Stock Outlook Looks Promising
Feb 08 2026
Yahoo Finance
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
Jan 31 2026
Fool
Show More News
